Premium
Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction
Author(s) -
Ljungman Per
Publication year - 2004
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2004.04845.x
Subject(s) - cytomegalovirus , medicine , immunology , population , transplantation , asymptomatic , transmission (telecommunications) , blood product , immunosuppression , human cytomegalovirus , intensive care medicine , virus , viral disease , herpesviridae , surgery , environmental health , electrical engineering , engineering
Cytomegalovirus (CMV) transmission remains a particular concern for immunocompromised patients, such as those undergoing bone marrow transplantation or receiving chemotherapy. It is of major importance for CMV seronegative patients that the risk of CMV transmission with blood products is minimized. The currently available techniques, use of CMV-seronegative blood products and leucocytereduction by filtration, have limitations. Pathogen inactivation is the newest approach to making blood safer. Several technologies are already available or in development. The final choice of a technique will most likely depend on the risk for severe CMV disease in the patient population as well as efficacy, safety, and costs of the chosen techniques.